Background and Objectives: Alloantibodies against the granulocyte-specific NA antigens play an important role in alloimmune neonatal neutropenia. As the NA system is located on the FcγRIIIb, the influence of NA-specific antibodies on granulocyte function is of special interest. Materials and Methods: We tested alloantisera specific for NA1 and NA2 for their ability to influence FcγR-mediated phagocytosis of polymorphonuclear neutrophils by use of different FcγR-specific targets. Red blood cells coated with human IgG anti-D served as specific targets for FcγRI-mediated phagocytosis while mouse IgG1 anti-glycophorin A was used to coat red blood cells (RBCs) to obtain FcγRII specific targets. To test for a hypothetical induction of phagocytosis by FcγRIIIb we used D-- RBCs coated with human monoclonal anti-D as target cells for unprimed neutrophils. Results: Granulocyte phagocytosis was directly induced by FcγRI and FcγRII but not by FcγRIIIb. NA1 alloantisera significantly inhibited FcγRI-mediated phagocytosis of IFN-γ-stimulated neutrophils if the corresponding antigen was expressed. Conversely, NA2 alloantisera inhibited FcγRI-mediated phagocytosis in NA2-positive individuals. There was no effect of NA1- and NA2-specific alloantibodies on FcγRII-mediated phagocytosis. Conclusion: NA-specific alloantisera inhibit the FcγRI-induced phagocytosis in primed neutrophils, but they do not significantly inhibit their FcγRIIa-specific phagocytosis of mIgG1-coated RBCs.

1.
Huizinga TWJ, Kleijer M, Tetteroo PAT, Roos F, von dem Borne AEGKr: Biallelic neutrophil NA-antigen system is associated with a polymorphism on the phosphoinositol-linked Fcγ receptor III (CD16). Blood 1990;75:213–217.
2.
Anderson CL, Looney RJ: Human leukocyte IgF Fc receptors. Immunol Today 1986;7:264–266.
3.
Salmon JE, Brogle NL, Edberg JC, Kimberly RP: Fcγ receptor III induces actin polymerization in human neutrophils and primes phagocytosis mediated by Fcγ receptor II. J Immunol 1991;146:997–1004.
4.
Edberg JC, Kimberly RP: Receptor specific probes for the study of Fcγ receptor specific function. J Immunol Methods 1992;148:179–187.
5.
Petroni KC, Shen L, Guyre PM: Modulation of human polymorphonuclear leukocytes, IgG Fc receptors and Fc receptor-mediated functions by IFN-γ and glucocorticoids. J Immunol 1988;140:3467–3472.
6.
Flesch BK, Achtert G, Neppert J: Inhibition of monocyte and polymorphonuclear granulocyte immune phagocytosis by monoclonal antibodies specific for FcγRI, II and III. Ann Hematol 1997;74:15–22.
7.
Mulder AHL, Heeringa P, Brouwer E, Limburg PC, Kallenberg CGM: Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): A FcγRII-dependent process. Clin Exp Immunol 1994;98:270–278.
8.
Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP: Antineutrophil cytoplasmic antibodies engage and activate human neutrophils via FcγRIIa. J Immunol 1994;153:1271–1280.
9.
Bux J, Dickmann JO, Stockert U, Mueller-Eckhardt C: Influence of granulocyte antibodies on granulocyte function. Vox Sang 1993;64:220–225.
10.
Kumpel BM: In vitro functional activity of IgG1 and IgG3 polyclonal and monoclonal anti-D. Vox Sang 1997;72:45–51.
11.
Fleit HB, Wright SD, Unkeless JC: Human neutrophil Fcγ receptor distribution and structure. Proc Natl Acad Sci USA 1982;79:3275–3279.
12.
Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A: Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens – new tools for genetic analysis. Cell 1978;14:9–20.
13.
Kurlander RJ: Blockade of Fc receptor-mediated binding to U-937 cells by murine monoclonal antibodies directed against a variety of surface antigens. J Immunol 1983;131:140–147.
14.
Neppert J, Marquard F, Mueller-Eckhardt C: Murine monoclonal antibodies and human alloantisera specific for HLA inhibit monocyte phagocytosis of anti-D-sensitized human red blood cells. Eur J Immunol 1985;15:559–563.
15.
Verheugt FWA, von dem Borne AEGK, van Noord-Bokhorst JC, van Elven EH, Engelfriet CP: Serological, immunochemical and immunocytological properties of granulocyte antibodies. Vox Sang 1978;35:294–303.
16.
Fanger MW, Shen L, Graziano RF, Guyre PM: Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 1989;10:92–99.
17.
Ravetch JV, Perussia B: Alternative membrane forms of FcγRIII(CD16) on human natural killer cells and neutrophils. J Exp Med 1989;170:481–497.
18.
Salmon JE, Edberg JC, Kimberly RP: Fcγ receptor III on human neutrophils. J Clin Invest 1990;85:1287–1295.
19.
Bredius RGM, Fijen CAP, de Haas M, Kuijper EJ, Weening RS, van de Winkel JGJ, Out TA: Role of neutrophil FcγRIIa (CD32) and FcγRIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsionized bacteria and erythrocytes. Immunology 1994;83:624–630.
20.
Wiener E, Dellow RA, Mawas F, Rodeck CH: Role of FcγRIIa (CD32) in IgG antiRhD-mediated red cell phagocytosis in vitro. Transfus Med 1996;6:235–241.
21.
Hulett MD, Hogarth PM: Molecular basis of Fc receptor function. Adv Immunol 1994;57:1–127.
22.
Warmerdam PAM, van de Winkel JGJ, Vlug A, Westerdaal NAC, Capel PJA: A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding. J Immunol 1991;147:1338–1343.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.